Tiziana Life Sciences Ltd. - ADR

Name: Tiziana Life Sciences Ltd. - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Tiziana Life Sciences Ltd. - ADR

Stock Card

$0.97

$0.04 (4.62%)

As on 03-Sep-2026 16:25EDT

Market cap

$129 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

2643.1

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Tiziana Life Sciences - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.95 High: 1.05

52 Week Range

Low: 0.87 High: 2.35

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-11 Mln
ROE

-9.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-6
Debt to Equity

8.8
Book Value

$0
EPS

$-0.3
Face value

--
Shares outstanding

127,259,131

10 Years Aggregate

CFO

$-106.83 Mln

EBITDA

$-130.10 Mln

Net Profit

$-138.53 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Tiziana Life Sciences - ADR	-34.6	-5.4	-28.3	-46.5	8.7	-13.4	--
BSE Sensex^*	-9.3	-2.3	3.3	-4.7	5.5	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 03-Sep-2026 | *As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
Tiziana Life Sciences - ADR	114.0	-6.4	-37.5	-52.5	87.0	-27.5
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Tiziana Life Sciences - ADR	1.0	128.5	0.0	-18.4	--	-924.3	--	2,643.1
Kiniksa Pharmaceuticals Ltd. Class A (KNSA)	80.5	6,092.1	840.9	80.7	13.1	13.2	78.9	9.5

Shareholding Pattern

View Details

About Tiziana Life Sciences - ADR

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human... anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom. Read more

Founder, Executive Chairman & Interim CEO

Mr. Gabriele Marco Antonio Cerrone M.B.A.
Founder, Executive Chairman & Interim CEO

Mr. Gabriele Marco Antonio Cerrone M.B.A.
Headquarters

London
Website

https://www.tizianalifesciences.com

FAQs for Tiziana Life Sciences - ADR

What is the current share price of Tiziana Life Sciences Ltd - ADR Today?

The share price of Tiziana Life Sciences Ltd - ADR is $0.97 (NASDAQ) as of 03-Sep-2026 16:25 EDT. Tiziana Life Sciences Ltd - ADR has given a return of 8.7% in the last 3 years.

What is the current PB & PE ratio of Tiziana Life Sciences Ltd - ADR?

Since, TTM earnings of Tiziana Life Sciences Ltd - ADR is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-4.72	1,673.77
2024	-3.03	9.12
2023	-1.29	5.19
2022	-1.59	1.54
2021	-3.11	2.38

What is the 52 Week High and Low of Tiziana Life Sciences Ltd - ADR?

The 52-week high and low of Tiziana Life Sciences Ltd - ADR are Rs 2.35 and Rs 0.87 as of 04-Sep-2026.

What is the market cap of Tiziana Life Sciences Ltd - ADR?

Tiziana Life Sciences Ltd - ADR has a market capitalisation of $ 129 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Tiziana Life Sciences Ltd - ADR?

Before investing in Tiziana Life Sciences Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.